Your current location:Home>About Qifang>FAQ

Frequently Asked Questions

Company Information

What kind of company is Qifang Pharmaceutical?

Guangdong Qifang Pharmaceutical Co., Ltd., founded in 2003 and headquartered in Guangzhou, is a pharmaceutical enterprise integrating R&D, registration, manufacturing, marketing, and promotion. Its business covers drug registration agency services, pharmaceutical manufacturing, and nationwide sales and promotion.

What is the development history of Qifang Pharmaceutical?

Since its founding in 2003, Qifang Pharmaceutical has continued to build its presence along the pharmaceutical industry chain. In 2011, it established Guangzhou Weisibao Pharmaceutical Co., Ltd. for the production of traditional Chinese patent medicines. In 2016, it established Shumeiqi Chengdu Biotechnology Co., Ltd. to strengthen its drug R&D capabilities. In 2020, it established Qingyue Shiguang Technology Co., Ltd. to focus on the eye health sector.

Where is Qifang Pharmaceutical headquartered?

The company is headquartered in Guangzhou, Guangdong Province, China.

How can I contact Qifang Pharmaceutical?

Service hotline: 020-37607100. You may also leave a message online via the "Contact Us" page of this website.

Products & Medication Inquiries

What are the core products of Qifang Pharmaceutical?

Core products include Xianjingtong® Fosphenytoin Sodium Concentrated Injection, Qifang® Compound Xueshuantong Dripping Pills, Shadaniding® Levocarnitine, and more.

What is Qifang® Compound Xueshuantong Dripping Pills?

Qifang® Compound Xueshuantong Dripping Pills is a traditional Chinese patent medicine that promotes blood circulation and removes blood stasis. Please refer to the package insert or consult a physician for specific indications.

What is Xianjingtong® Fosphenytoin Sodium Concentrated Injection?

Xianjingtong® Fosphenytoin Sodium Concentrated Injection is an antiepileptic drug and a third-generation improved formulation of phenytoin sodium. Phenytoin sodium is listed in the First List of Children's Medicines Encouraged for R&D and Application, and Xianjingtong® Fosphenytoin Sodium Concentrated Injection has been included in the 2025 National Reimbursement Drug List (negotiated category, Class B). It is exclusively distributed nationwide by Qifang Pharmaceutical, with Shumeiqi Chengdu Biotechnology Co., Ltd. as the Marketing Authorization Holder. Please refer to the package insert or consult a physician for details.

Talent recruitment | Online Message| powered by:www.gdqifang.net
Guangdong Qifang Medicine Co., Ltd. copyright Service Phone:020-37607100
Scan the qr code
Pay attention to Qifang